Skip to main content

Advertisement

SpringerLink
Log in

Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Erratum to this article was published on 30 September 2016

Abstract

Racial disparities in breast cancer mortality persist and are likely related to multiple factors. Over the past decade, progress has been made in treating metastatic breast cancer, particularly in younger women. Whether disparities exist in this population is unknown. Using administrative claims data between 2000 and 2011 (OptumInsight, Eden Prairie, MN) of members insured through a large national US health insurer, we identified women aged 25–64 years diagnosed with incident metastatic breast cancer diagnosed between November 1, 2000, and December 31, 2008. We examined time from diagnosis to death, with up to 3 years of follow-up. We stratified analyses by geocoded race and socio-economic status, age-at-diagnosis, morbidity score, US region of residence, urban/non-urban, and years of diagnosis. We constructed Kaplan–Meier survival plots and analyzed all-cause mortality using multivariate Cox proportional hazard models. Among 6694 women with incident metastatic breast cancer (78 % Caucasian, 4 % African American, and 18 % other), we found higher mortality rates among women residing in predominantly African American versus Caucasian neighborhoods (hazard ratio (HR) 1.84; 95 % confidence interval, CI 1.39–2.45), women with high versus lower morbidity (HR 1.30 [1.12–1.51]), and women whose incident metastatic diagnosis was during 2000–2004 versus 2005–2008 (HR 1.60 [1.39–1.83]). Caucasian (HR 0.61 [0.52–0.71]) but not African American women (HR not significant) experienced improved mortality in 2005–2008 versus 2000–2004. Despite insured status, African American women and women with multi-morbidity had poorer survival. Only Caucasian women had improved mortality over time. Modifiable risk factors for increased mortality need to be addressed in order to reduce disparities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Source: adjusted from [31]

Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cancer facts & figures 2016 [Internet]. Atlanta: American Cancer Society (2016) http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf

  2. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 24:1495–1506

    Article  Google Scholar 

  3. Group EBCTC, others (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 365:1687–1717

    Article  Google Scholar 

  4. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

    Article  PubMed  Google Scholar 

  5. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA et al (2015) Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. JNCI J Natl Cancer Inst 107:djv048–djv048

    Article  PubMed  Google Scholar 

  6. Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M (2013) Prognostic factors and survival in metastatic breast cancer: a single institution experience. Rep Pract Oncol Radiother 18:127–132

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277

    Article  PubMed  Google Scholar 

  8. Alanko A, Heinonen E, Scheinin T, Tolppanen E-M, Vihko R (1985) Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696–1700

    Article  CAS  PubMed  Google Scholar 

  9. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979

    Article  PubMed  Google Scholar 

  10. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10:20–29

    Article  PubMed  Google Scholar 

  11. Extra J-M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15:799–809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244

    Article  CAS  PubMed  Google Scholar 

  13. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol 23:4265–4274

    Article  CAS  Google Scholar 

  14. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol Off J Am Soc Clin Oncol 29:264–271

    Article  CAS  Google Scholar 

  15. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2015) Breast cancer statistics, 2015: convergence of incidence rates between black and white women: breast cancer statistics. CA Cancer J Clin 66(1):31–42. doi:10.3322/caac.21320

    Article  PubMed  Google Scholar 

  16. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U (2008) Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat 107:405–414

    Article  CAS  PubMed  Google Scholar 

  17. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M et al (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res BCR 11:R18

    Article  PubMed  Google Scholar 

  18. Danforth DN (2013) Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res BCR 15:208

    Article  PubMed  Google Scholar 

  19. Newman LA (2005) Breast cancer in African-American women. Oncologist 10:1–14

    Article  PubMed  Google Scholar 

  20. Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Int Med 163:49–56

    Article  Google Scholar 

  21. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439–448

    Article  PubMed  Google Scholar 

  22. Huo D, Ikpatt F, Khramtsov A, Dangou J-M, Nanda R, Dignam J et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 27:4515–4521

    Article  CAS  Google Scholar 

  23. Rugo HS, Brufsky AM, Yood MU, Tripathy D, Kaufman PA, Mayer M et al (2013) Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141:461–470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Johnson ET (2002) Breast cancer racial differences before age 40-implications for screening. J Natl Med Assoc 94:149–156

    PubMed  PubMed Central  Google Scholar 

  25. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV (2005) Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health 95:312–323

    Article  PubMed  PubMed Central  Google Scholar 

  26. O’Keefe EB, Meltzer JP, Bethea TN (2015) Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000–2010. Front Public Health 3:51

    PubMed  PubMed Central  Google Scholar 

  27. Aizer AA, Wilhite TJ, Chen M-H, Graham PL, Choueiri TK, Hoffman KE et al (2014) Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120:1532–1539

    Article  PubMed  Google Scholar 

  28. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD (2011) Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest 29:573–584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong Y-N et al (2016) Time to surgery and breast cancer survival in the United States. JAMA Oncol 2:330–339

    Article  PubMed  Google Scholar 

  30. Social Security Administration (2016) Death Master File (DMF) [Internet]. Soc Secur Adm. http://www.ssdmf.com

  31. Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou Z-Y, Latremouille Viau D et al (2014) Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist 19:901–908

    Article  PubMed  PubMed Central  Google Scholar 

  32. Reid RJ, Roos NP, MacWilliam L, Frohlich N, Black C (2002) Assessing population health care need using a claims-based ACG morbidity measure: a validation analysis in the Province of Manitoba. Health Serv Res 37:1345–1364

    Article  PubMed  PubMed Central  Google Scholar 

  33. The Johns Hopkins ACG case-mix system reference manual, Version 7.0 (2005) The Johns Hopkins University, Baltimore, MD

  34. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV (2003) Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures–the public health disparities geocoding project. Am J Public Health 93:1655–1671

    Article  PubMed  PubMed Central  Google Scholar 

  35. United States Census Bureau (1994) Geographical areas reference manual. United States Census Bureau, Washington

    Google Scholar 

  36. US Department of Agriculture. Rural-Urban Commuting Area Codes [Internet] Econ Res Serv. 01/20166 [cited 2016 Jan 10]. http://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx

  37. Pankratz VS, de Andrade M, Therneau TM (2005) Random-effects Cox proportional hazards model: general variance components methods for time-to-event data. Genet Epidemiol 28:97–109

    Article  PubMed  Google Scholar 

  38. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G (2010) Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 119:621–631

    Article  CAS  PubMed  Google Scholar 

  39. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742–1750

    Article  PubMed  Google Scholar 

  40. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 21:2169–2174

    Article  CAS  Google Scholar 

  41. Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389–397

    Article  CAS  PubMed  Google Scholar 

  42. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol Off J Am Soc Clin Oncol 28:92–98

    Article  CAS  Google Scholar 

  43. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H et al (2008) Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840–Cancer and Leukemia group B. J Clin Oncol 26:2659–2665

    Article  PubMed  PubMed Central  Google Scholar 

  44. Keegan TH, Kurian AW, Gali K, Tao L, Lichtensztajn DY, Hershman DL, et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. J Inf [Internet] [cited 2015 Apr 30] 105. http://ajph.aphapublications.org/doi/10.2105/AJPH.2014.302406

  45. Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black: White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38:118–123

    Article  PubMed  Google Scholar 

  46. Ooi SL, Martinez ME, Li CI (2011) Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 127:729–738

    Article  PubMed  Google Scholar 

  47. Swede H, Sarwar A, Magge A, Braithwaite D, Cook LS, Gregorio DI et al (2016) Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. Cancer Causes Control CCC 27:627–636

    Article  PubMed  Google Scholar 

  48. Nelson SH, Marinac CR, Patterson RE, Nechuta SJ, Flatt SW, Caan BJ et al (2016) Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors. Breast Cancer Res Treat 155:551–557

    Article  PubMed  Google Scholar 

  49. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among White and Black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898

    Article  PubMed  PubMed Central  Google Scholar 

  50. Polednak AP (2004) Racial differences in mortality from obesity-related chronic diseases in US women diagnosed with breast cancer. Ethn Dis 14:463–468

    PubMed  Google Scholar 

  51. DeSantis C, Jemal A, Ward E, Thun MJ (2008) Temporal trends in breast cancer mortality by state and race. Cancer Causes Control CCC 19:537–545

    Article  PubMed  Google Scholar 

  52. Henry KA, Sherman R, Farber S, Cockburn M, Goldberg DW, Stroup AM (2013) The joint effects of census tract poverty and geographic access on late-stage breast cancer diagnosis in 10 US States. Health Place 21:110–121

    Article  PubMed  Google Scholar 

  53. Keller D, Guilfoyle C, Sariego J (2011) Geographical influence on racial disparity in breast cancer presentation in the United States. Am Surg 77:933–936

    PubMed  Google Scholar 

  54. Tatalovich Z, Zhu L, Rolin A, Lewis DR, Harlan LC, Winn DM (2015) Geographic disparities in late stage breast cancer incidence: results from eight states in the United States. Int J Health Geogr [Internet] [cited 2015 Dec 1] 14:1. http://www.ij-healthgeographics.com/content/14/1/31

Download references

Acknowledgement

This work was supported by a grant from the National Cancer Institute under Grant No. R01CA172639 (PI: Wharam). Dr. Leopold’s salary was supported by the Thomas O. Pyle Research Scholarship from Harvard Medical School and Harvard Pilgrim Health Care Institute.

Author information

Authors and Affiliations

  1. Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Landmark Center 401 Park Drive Suite, Boston, MA, 02215, USA

    Christine Leopold, Anita K. Wagner, Fang Zhang, Christine Y. Lu, Larissa Nekhlyudov, Dennis-Ross Degnan & J. Frank Wharam

  2. Health Service Research, Ontario Institute for Cancer Research, Toronto, ON, USA

    Craig Earle

  3. Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    Larissa Nekhlyudov

Authors
  1. Christine Leopold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita K. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine Y. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Craig Earle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Larissa Nekhlyudov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dennis-Ross Degnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Frank Wharam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Leopold.

Ethics declarations

Conflict of interest

Dr. Wagner and Dr. Ross-Degnan did consultancy work for IMS Consulting Group. All other authors have no conflicts to declare.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s10549-016-3988-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leopold, C., Wagner, A.K., Zhang, F. et al. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat 158, 333–340 (2016). https://doi.org/10.1007/s10549-016-3875-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3875-z

Keywords

Search

Navigation